Top

Published in:

Open Access 01-12-2012 | Review

Technical challenges and limitations of current mouse models of ovarian cancer

Authors: Kenneth Garson, Lisa F Gamwell, Elizabeth MG Pitre, Barbara C Vanderhyden

Published in: Journal of Ovarian Research | Issue 1/2012

Abstract

The development of genetically engineered models (GEM) of epithelial ovarian cancer (EOC) has been very successful, with well validated models representing high grade and low grade serous adenocarcinomas and endometrioid carcinoma (EC). Most of these models were developed using technologies intended to target the ovarian surface epithelium (OSE), the cell type long believed to be the origin of EOC. More recent evidence has highlighted what is likely a more prevalent role of the secretory cell of the fallopian tube in the ontogeny of EOC, however none of the GEM of EOC have demonstrated successful targeting of this important cell type.

The precise technologies exploited to develop the existing GEM of EOC are varied and carry with them advantages and disadvantages. The use of tissue specific promoters to model disease has been very successful, but the lack of any truly specific OSE or oviductal secretory cell promoters makes the outcomes of these models quite unpredictable. Effecting genetic change by the administration of adenoviral vectors expressing Cre recombinase may alleviate the perceived need for tissue specific promoters, however the efficiencies of infection of different cell types is subject to numerous biological parameters that may lead to preferential targeting of certain cell populations.

One important future avenue of GEM of EOC is the evaluation of the role of genetic modifiers. We have found that genetic background can lead to contrasting phenotypes in one model of ovarian cancer, and data from other laboratories have also hinted that the exact genetic background of the model may influence the resulting phenotype. The different genetic backgrounds may modify the biology of the tumors in a manner that will be relevant to human disease, but they may also be modifying parameters which impact the response of the host to the technologies employed to develop the model.

Available only for authorised users

Connolly DC, Hensley HH: Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents. Curr Protoc Pharmacol 2009, 45: 14 12 11–14 12 26.

Fong MY, Kakar SS: Ovarian cancer mouse models: a summary of current models and their limitations. J Ovarian Res 2009, 2: 12. 10.1186/1757-2215-2-12PubMedCentralPubMedCrossRef

Lu KH, Yates MS, Mok SC: The monkey, the hen, and the mouse: models to advance ovarian cancer chemoprevention. Cancer Prev Res (Phila) 2009, 2: 773–775. 10.1158/1940-6207.CAPR-09-0156CrossRef

Sale S: Genetically engineered mouse models of ovarian cancer and their utility in drug discovery. Curr Protoc Pharmacol 2009,Chapter 14(Unit 14):11.PubMed

King SM, Burdette JE: Evaluating the progenitor cells of ovarian cancer: analysis of current animal models. BMB Rep 2011, 44: 435–445. 10.5483/BMBRep.2011.44.7.435PubMedCentralPubMedCrossRef

Mullany LK, Richards JS: Minireview: animal models and mechanisms of ovarian cancer development. Endocrinology 2012, 153: 1585–1592. 10.1210/en.2011-2121PubMedCentralPubMedCrossRef

Shan W, Liu J: Epithelial ovarian cancer: focus on genetics and animal models. Cell Cycle 2009, 8: 731–735. 10.4161/cc.8.5.7848PubMedCrossRef

Garson K, Shaw TJ, Clark KV, Yao DS, Vanderhyden BC: Models of ovarian cancer–are we there yet? Mol Cell Endocrinol 2005, 239: 15–26. 10.1016/j.mce.2005.03.019PubMedCrossRef

Cheon DJ, Orsulic S: Mouse models of cancer. Annu Rev Pathol 2011, 6: 95–119. 10.1146/annurev.pathol.3.121806.154244PubMedCrossRef

10.

Bell DA: Origins and molecular pathology of ovarian cancer. Mod Pathol 2005,18(Suppl 2):S19–32.PubMedCrossRef

11.

Bell DA, Scully RE: Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 1994, 73: 1859–1864. 10.1002/1097-0142(19940401)73:7<1859::AID-CNCR2820730714>3.0.CO;2-LPubMedCrossRef

12.

Pothuri B, Leitao MM, Levine DA, Viale A, Olshen AB, Arroyo C, Bogomolniy F, Olvera N, Lin O, Soslow RA, et al.: Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One 2010, 5: e10358. 10.1371/journal.pone.0010358PubMedCentralPubMedCrossRef

13.

Auersperg N, Woo MM, Gilks CB: The origin of ovarian carcinomas: a developmental view. Gynecol Oncol 2008, 110: 452–454. 10.1016/j.ygyno.2008.05.031PubMedCrossRef

14.

Feeley KM, Wells M: Precursor lesions of ovarian epithelial malignancy. Histopathology 2001, 38: 87–95. 10.1046/j.1365-2559.2001.01042.xPubMedCrossRef

15.

Gendronneau G, Boucherat O, Aubin J, Lemieux M, Jeannotte L: The loss of Hoxa5 function causes estrous acyclicity and ovarian epithelial inclusion cysts. Endocrinology 2012, 153: 1484–1497. 10.1210/en.2011-1766PubMedCentralPubMedCrossRef

16.

Burdette JE, Oliver RM, Ulyanov V, Kilen SM, Mayo KE, Woodruff TK: Ovarian epithelial inclusion cysts in chronically superovulated CD1 and Smad2 dominant-negative mice. Endocrinology 2007, 148: 3595–3604. 10.1210/en.2007-0030PubMedCrossRef

17.

Cheng W, Liu J, Yoshida H, Rosen D, Naora H: Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 2005, 11: 531–537. 10.1038/nm1230PubMedCrossRef

18.

Dubeau L: The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol 1999, 72: 437–442. 10.1006/gyno.1998.5275PubMedCrossRef

19.

Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH: Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001, 195: 451–456. 10.1002/path.1000PubMedCrossRef

20.

Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V, Crucianelli R, Pasini B: Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol 2004, 23: 35–40. 10.1097/01.pgp.0000101082.35393.84PubMedCrossRef

21.

Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, et al.: A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007, 211: 26–35. 10.1002/path.2091PubMedCrossRef

22.

Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D, Crum CP: Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008, 26: 4160–4165. 10.1200/JCO.2008.16.4814PubMedCentralPubMedCrossRef

23.

Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP: A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008, 109: 168–173. 10.1016/j.ygyno.2008.01.012PubMedCentralPubMedCrossRef

24.

Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y, Crum CP: Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 2008, 27: 1–9. 10.1097/pgp.0b013e31814b191fPubMedCrossRef

25.

Crum CP, McKeon FD, Xian W: BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis. Int J Gynecol Cancer 2012,22(Suppl 1):S29–34.PubMedCrossRef

26.

Roh MH, Kindelberger D, Crum CP: Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol 2009, 33: 376–383. 10.1097/PAS.0b013e3181868904PubMedCrossRef

27.

Paik DY, Janzen DM, Schafenacker AM, Velasco VS, Shung MS, Cheng D, Huang J, Witte ON, Memarzadeh S: Stem-like epithelial cells are concentrated in the distal end of the fallopian tube: a site for injury and serous cancer initiation. Stem Cells 2012, 30: 2487–2497. 10.1002/stem.1207PubMedCentralPubMedCrossRef

28.

Gamwell LF, Collins O, Vanderhyden BC: The Mouse Ovarian Surface Epithelium Contains a Population of LY6A (SCA-1) Expressing Progenitor Cells That Are Regulated by Ovulation-Associated Factors. Biol Reprod 2012, 87: 80. 10.1095/biolreprod.112.100347PubMedCrossRef

29.

Virant-Klun I, Skutella T, Stimpfel M, Sinkovec J: Ovarian surface epithelium in patients with severe ovarian infertility: a potential source of cells expressing markers of pluripotent/multipotent stem cells. J Biomed Biotechnol 2011, 2011: 381928.PubMedCentralPubMedCrossRef

30.

Chang HL, MacLaughlin DT, Donahoe PK: Somatic stem cells of the ovary and their relationship to human ovarian cancers. Cambridge (MA): StemBook; 2008.

31.

Szotek PP, Chang HL, Brennand K, Fujino A, Pieretti-Vanmarcke R, Lo Celso C, Dombkowski D, Preffer F, Cohen KS, Teixeira J, Donahoe PK: Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Proc Natl Acad Sci U S A 2008, 105: 12469–12473. 10.1073/pnas.0805012105PubMedCentralPubMedCrossRef

32.

Motohara T, Masuko S, Ishimoto T, Yae T, Onishi N, Muraguchi T, Hirao A, Matsuzaki Y, Tashiro H, Katabuchi H, et al.: Transient depletion of p53 followed by transduction of c-Myc and K-Ras converts ovarian stem-like cells into tumor-initiating cells. Carcinogenesis 2011, 32: 1597–1606. 10.1093/carcin/bgr183PubMedCrossRef

33.

Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC: Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003, 63: 1389–1397.PubMed

34.

Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC, Themmen AP, Grootegoed JA: Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology 1995, 136: 4951–4962. 10.1210/en.136.11.4951PubMed

35.

Arango NA, Kobayashi A, Wang Y, Jamin SP, Lee HH, Orvis GD, Behringer RR: A mesenchymal perspective of Mullerian duct differentiation and regression in Amhr2-lacZ mice. Mol Reprod Dev 2008, 75: 1154–1162. 10.1002/mrd.20858PubMedCrossRef

36.

Kananen K, Markkula M, Rainio E, Su JG, Hsueh AJ, Huhtaniemi IT: Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin alpha-subunit promoter/simian virus T-antigen fusion gene: characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. Mol Endocrinol 1995, 9: 616–627. 10.1210/me.9.5.616PubMed

37.

Garson K, Macdonald E, Dube M, Bao R, Hamilton TC, Vanderhyden BC: Generation of tumors in transgenic mice expressing the SV40 T antigen under the control of ovarian-specific promoter 1. J Soc Gynecol Investig 2003, 10: 244–250. 10.1016/S1071-5576(03)00073-XPubMedCrossRef

38.

Dutertre M, Gouedard L, Xavier F, Long WQ, di Clemente N, Picard JY, Rey R: Ovarian granulosa cell tumors express a functional membrane receptor for anti-Mullerian hormone in transgenic mice. Endocrinology 2001, 142: 4040–4046. 10.1210/en.142.9.4040PubMed

39.

Miyoshi I, Takahashi K, Kon Y, Okamura T, Mototani Y, Araki Y, Kasai N: Mouse transgenic for murine oviduct-specific glycoprotein promoter-driven simian virus 40 large T-antigen: tumor formation and its hormonal regulation. Mol Reprod Dev 2002, 63: 168–176. 10.1002/mrd.10175PubMedCrossRef

40.

Woo MM, Gilks CB, Verhage HG, Longacre TA, Leung PC, Auersperg N: Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts. Gynecol Oncol 2004, 93: 315–319. 10.1016/j.ygyno.2004.01.047PubMedCrossRef

41.

Woo MM, Alkushi A, Verhage HG, Magliocco AM, Leung PC, Gilks CB, Auersperg N: Gain of OGP, an estrogen-regulated oviduct-specific glycoprotein, is associated with the development of endometrial hyperplasia and endometrial cancer. Clin Cancer Res 2004, 10: 7958–7964. 10.1158/1078-0432.CCR-04-1261PubMedCrossRef

42.

Liang S, Yang N, Pan Y, Deng S, Lin X, Yang X, Katsaros D, Roby KF, Hamilton TC, Connolly DC, et al.: Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation. PLoS One 2009, 4: e4295. 10.1371/journal.pone.0004295PubMedCentralPubMedCrossRef

43.

Bristol-Gould SK, Hutten CG, Sturgis C, Kilen SM, Mayo KE, Woodruff TK: The development of a mouse model of ovarian endosalpingiosis. Endocrinology 2005, 146: 5228–5236. 10.1210/en.2005-0697PubMedCrossRef

44.

Yang DH, Fazili Z, Smith ER, Cai KQ, Klein-Szanto A, Cohen C, Horowitz IR, Xu XX: Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background. Am J Pathol 2006, 169: 258–267. 10.2353/ajpath.2006.060036PubMedCentralPubMedCrossRef

45.

Chodankar R, Kwang S, Sangiorgi F, Hong H, Yen HY, Deng C, Pike MC, Shuler CF, Maxson R, Dubeau L: Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr Biol 2005, 15: 561–565. 10.1016/j.cub.2005.01.052PubMedCrossRef

46.

Hu Y, Ghosh S, Amleh A, Yue W, Lu Y, Katz A, Li R: Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 2005, 24: 8343–8348. 10.1038/sj.onc.1208985PubMedCrossRef

47.

Hong H, Yen HY, Brockmeyer A, Liu Y, Chodankar R, Pike MC, Stanczyk FZ, Maxson R, Dubeau L: Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer. Cancer Res 2010, 70: 221–228. 10.1158/0008-5472.CAN-09-3232PubMedCentralPubMedCrossRef

48.

Tanaka Y, Park JH, Tanwar PS, Kaneko-Tarui T, Mittal S, Lee HJ, Teixeira JM: Deletion of tuberous sclerosis 1 in somatic cells of the murine reproductive tract causes female infertility. Endocrinology 2012, 153: 404–416. 10.1210/en.2011-1191PubMedCentralPubMedCrossRef

49.

Tanwar PS, Lee HJ, Zhang L, Zukerberg LR, Taketo MM, Rueda BR, Teixeira JM: Constitutive activation of Beta-catenin in uterine stroma and smooth muscle leads to the development of mesenchymal tumors in mice. Biol Reprod 2009, 81: 545–552. 10.1095/biolreprod.108.075648PubMedCentralPubMedCrossRef

50.

Jamin SP, Arango NA, Mishina Y, Hanks MC, Behringer RR: Requirement of Bmpr1a for Mullerian duct regression during male sexual development. Nat Genet 2002, 32: 408–410. 10.1038/ng1003PubMedCrossRef

51.

Fan HY, Liu Z, Paquet M, Wang J, Lydon JP, DeMayo FJ, Richards JS: Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells. Cancer Res 2009, 69: 6463–6472. 10.1158/0008-5472.CAN-08-3363PubMedCentralPubMedCrossRef

52.

Fan HY, Liu Z, Cahill N, Richards JS: Targeted disruption of Pten in ovarian granulosa cells enhances ovulation and extends the life span of luteal cells. Mol Endocrinol 2008, 22: 2128–2140. 10.1210/me.2008-0095PubMedCentralPubMedCrossRef

53.

Lague MN, Paquet M, Fan HY, Kaartinen MJ, Chu S, Jamin SP, Behringer RR, Fuller PJ, Mitchell A, Dore M, et al.: Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Carcinogenesis 2008, 29: 2062–2072. 10.1093/carcin/bgn186PubMedCentralPubMedCrossRef

54.

Mullany LK, Liu Z, King ER, Wong KK, Richards JS: Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival. Endocrinology 2012, 153: 1638–1648. 10.1210/en.2011-2131PubMedCentralPubMedCrossRef

55.

Daikoku T, Jackson L, Besnard V, Whitsett J, Ellenson LH, Dey SK: Cell-specific conditional deletion of Pten in the uterus results in differential phenotypes. Gynecol Oncol 2011, 122: 424–429. 10.1016/j.ygyno.2011.04.022PubMedCentralPubMedCrossRef

56.

Tanwar PS, Zhang L, Kaneko-Tarui T, Curley MD, Taketo MM, Rani P, Roberts DJ, Teixeira JM: Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/beta-catenin and PTEN. PLoS One 2011, 6: e20715. 10.1371/journal.pone.0020715PubMedCentralPubMedCrossRef

57.

Richards JS, Fan HY, Liu Z, Tsoi M, Lague MN, Boyer A, Boerboom D: Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis. Oncogene 2012, 31: 1504–1520. 10.1038/onc.2011.341PubMedCentralPubMedCrossRef

58.

Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM: High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A 2012, 109: 3921–3926. 10.1073/pnas.1117135109PubMedCentralPubMedCrossRef

59.

Gonzalez G, Behringer RR: Dicer is required for female reproductive tract development and fertility in the mouse. Mol Reprod Dev 2009, 76: 678–688. 10.1002/mrd.21010PubMedCentralPubMedCrossRef

60.

Lei L, Jin S, Gonzalez G, Behringer RR, Woodruff TK: The regulatory role of Dicer in folliculogenesis in mice. Mol Cell Endocrinol 2010, 315: 63–73. 10.1016/j.mce.2009.09.021PubMedCentralPubMedCrossRef

61.

Tanwar PS, Kaneko-Tarui T, Zhang L, Tanaka Y, Crum CP, Teixeira JM: Stromal Liver Kinase B1 [STK11] Signaling Loss Induces Oviductal Adenomas and Endometrial Cancer by Activating Mammalian Target of Rapamycin Complex 1. PLoS Genet 2012, 8: e1002906. 10.1371/journal.pgen.1002906PubMedCentralPubMedCrossRef

62.

Siegenthaler JA, Tremper-Wells BA, Miller MW: Foxg1 haploinsufficiency reduces the population of cortical intermediate progenitor cells: effect of increased p21 expression. Cereb Cortex 2008, 18: 1865–1875. 10.1093/cercor/bhm209PubMedCentralPubMedCrossRef

63.

MacLean HE, Chiu WS, Ma C, McManus JF, Davey RA, Cameron R, Notini AJ, Zajac JD: A floxed allele of the androgen receptor gene causes hyperandrogenization in male mice. Physiol Genomics 2008, 33: 133–137. 10.1152/physiolgenomics.00260.2007PubMedCrossRef

64.

Petit FG, Jamin SP, Kurihara I, Behringer RR, DeMayo FJ, Tsai MJ, Tsai SY: Deletion of the orphan nuclear receptor COUP-TFII in uterus leads to placental deficiency. Proc Natl Acad Sci U S A 2007, 104: 6293–6298. 10.1073/pnas.0702039104PubMedCentralPubMedCrossRef

65.

Lee JY, Ristow M, Lin X, White MF, Magnuson MA, Hennighausen L: RIP-Cre revisited, evidence for impairments of pancreatic beta-cell function. J Biol Chem 2006, 281: 2649–2653.PubMedCrossRef

66.

Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY: Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003, 63: 3459–3463.PubMed

67.

Clark-Knowles KV, Senterman MK, Collins O, Vanderhyden BC: Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS One 2009, 4: e8534. 10.1371/journal.pone.0008534PubMedCentralPubMedCrossRef

68.

Quinn BA, Brake T, Hua X, Baxter-Jones K, Litwin S, Ellenson LH, Connolly DC: Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS One 2009, 4: e8404. 10.1371/journal.pone.0008404PubMedCentralPubMedCrossRef

69.

Xing D, Scangas G, Nitta M, He L, Xu X, Ioffe YJ, Aspuria PJ, Hedvat CY, Anderson ML, Oliva E, et al.: A role for BRCA1 in uterine leiomyosarcoma. Cancer Res 2009, 69: 8231–8235. 10.1158/0008-5472.CAN-09-2543PubMedCentralPubMedCrossRef

70.

Szabova L, Yin C, Bupp S, Guerin TM, Schlomer JJ, Householder DB, Baran ML, Yi M, Song Y, Sun W, et al.: Perturbation of Rb, p53 and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res 2012, 72: 4141–4153. 10.1158/0008-5472.CAN-11-3834PubMedCentralPubMedCrossRef

71.

Dannenberg JH, Schuijff L, Dekker M, van der Valk M, te Riele H: Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Genes Dev 2004, 18: 2952–2962. 10.1101/gad.322004PubMedCentralPubMedCrossRef

72.

Saenz Robles MT, Symonds H, Chen J, Van Dyke T: Induction versus progression of brain tumor development: differential functions for the pRB- and p53-targeting domains of simian virus 40 T antigen. Mol Cell Biol 1994, 14: 2686–2698. 10.1128/MCB.14.4.2686PubMedCentralPubMedCrossRef

73.

Stubdal H, Zalvide J, Campbell KS, Schweitzer C, Roberts TM, DeCaprio JA: Inactivation of pRB-related proteins p130 and p107 mediated by the J domain of simian virus 40 large T antigen. Mol Cell Biol 1997, 17: 4979–4990.PubMedCentralPubMed

74.

Laviolette LA, Garson K, Macdonald EA, Senterman MK, Courville K, Crane CA, Vanderhyden BC: 17beta-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer. Endocrinology 2010, 151: 929–938. 10.1210/en.2009-0602PubMedCrossRef

75.

Ahuja D, Saenz-Robles MT, Pipas JM: SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 2005, 24: 7729–7745. 10.1038/sj.onc.1209046PubMedCrossRef

76.

Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T: Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005, 11: 63–70. 10.1038/nm1173PubMedCrossRef

77.

Kinross KM, Brown DV, Kleinschmidt M, Jackson S, Christensen J, Cullinane C, Hicks RJ, Johnstone RW, McArthur GA: In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. Mol Cancer Ther 2011, 10: 1440–1449. 10.1158/1535-7163.MCT-11-0240PubMedCrossRef

78.

Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, Cubillos-Ruiz JR, Jacobs AC, Gonzalez JL, Weaver J, et al.: Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012, 209: 495–506. 10.1084/jem.20111413PubMedCentralPubMedCrossRef

79.

Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis T, et al.: An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 2012, 122: 553–557. 10.1172/JCI59309PubMedCentralPubMedCrossRef

80.

Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, et al.: Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007, 11: 321–333. 10.1016/j.ccr.2007.02.016PubMedCrossRef

81.

Wu R, Hu TC, Rehemtulla A, Fearon ER, Cho KR: Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res 2011, 17: 7359–7372. 10.1158/1078-0432.CCR-11-1388PubMedCentralPubMedCrossRef

82.

Zhu Y, Maric J, Nilsson M, Brannstrom M, Janson PO, Sundfeldt K: Formation and barrier function of tight junctions in human ovarian surface epithelium. Biol Reprod 2004, 71: 53–59. 10.1095/biolreprod.103.022913PubMedCrossRef

83.

Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275: 1320–1323. 10.1126/science.275.5304.1320PubMedCrossRef

84.

Wickham TJ, Mathias P, Cheresh DA, Nemerow GR: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993, 73: 309–319. 10.1016/0092-8674(93)90231-EPubMedCrossRef

85.

Cohen CJ, Shieh JT, Pickles RJ, Okegawa T, Hsieh JT, Bergelson JM: The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci U S A 2001, 98: 15191–15196. 10.1073/pnas.261452898PubMedCentralPubMedCrossRef

86.

Pearson AS, Koch PE, Atkinson N, Xiong M, Finberg RW, Roth JA, Fang B: Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin Cancer Res 1999, 5: 4208–4213.PubMed

87.

Excoffon KJ, Gansemer ND, Mobily ME, Karp PH, Parekh KR, Zabner J: Isoform-specific regulation and localization of the coxsackie and adenovirus receptor in human airway epithelia. PLoS One 2010, 5: e9909. 10.1371/journal.pone.0009909PubMedCentralPubMedCrossRef

88.

Lutschg V, Boucke K, Hemmi S, Greber UF: Chemotactic antiviral cytokines promote infectious apical entry of human adenovirus into polarized epithelial cells. Nat Commun 2011, 2: 391.PubMedCrossRef

89.

Johansson C, Jonsson M, Marttila M, Persson D, Fan XL, Skog J, Frangsmyr L, Wadell G, Arnberg N: Adenoviruses use lactoferrin as a bridge for CAR-independent binding to and infection of epithelial cells. J Virol 2007, 81: 954–963. 10.1128/JVI.01995-06PubMedCentralPubMedCrossRef

90.

Arici A, Oral E, Bukulmez O, Buradagunta S, Engin O, Olive DL: Interleukin-8 expression and modulation in human preovulatory follicles and ovarian cells. Endocrinology 1996, 137: 3762–3769. 10.1210/en.137.9.3762PubMed

91.

Palter SF, Mulayim N, Senturk L, Arici A: Interleukin-8 in the human fallopian tube. J Clin Endocrinol Metab 2001, 86: 2660–2667. 10.1210/jc.86.6.2660PubMedCrossRef

92.

Teng CT, Beard C, Gladwell W: Differential expression and estrogen response of lactoferrin gene in the female reproductive tract of mouse, rat, and hamster. Biol Reprod 2002, 67: 1439–1449. 10.1095/biolreprod.101.002089PubMedCrossRef

93.

Yanaihara A, Mitsukawa K, Iwasaki S, Otsuki K, Kawamura T, Okai T: High concentrations of lactoferrin in the follicular fluid correlate with embryo quality during in vitro fertilization cycles. Fertil Steril 2007, 87: 279–282. 10.1016/j.fertnstert.2006.06.025PubMedCrossRef

94.

Saito F, Tashiro H, To Y, Ohtake H, Ohba T, Suzuki A, Katabuchi H: Mutual contribution of Pten and estrogen to endometrial carcinogenesis in a PtenloxP/loxP mouse model. Int J Gynecol Cancer 2011, 21: 1343–1349. 10.1097/IGC.0b013e31822d2a8aPubMedCrossRef

95.

Hunter KW: Mouse models of cancer: does the strain matter? Nat Rev Cancer 2012, 12: 144–149.PubMed

96.

Churchill GA, Airey DC, Allayee H, Angel JM, Attie AD, Beatty J, Beavis WD, Belknap JK, Bennett B, Berrettini W, et al.: The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet 2004, 36: 1133–1137. 10.1038/ng1104-1133PubMedCrossRef

97.

Weaver Z, Montagna C, Xu X, Howard T, Gadina M, Brodie SG, Deng CX, Ried T: Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 2002, 21: 5097–5107. 10.1038/sj.onc.1205636PubMedCrossRef

98.

Laviolette LA, Ethier JF, Senterman MK, Devine PJ, Vanderhyden BC: Induction of a menopausal state alters the growth and histology of ovarian tumors in a mouse model of ovarian cancer. Menopause 2011, 18: 549–557. 10.1097/gme.0b013e3181fca1b6PubMedCrossRef

Title: Technical challenges and limitations of current mouse models of ovarian cancer
Authors: Kenneth Garson
Lisa F Gamwell
Elizabeth MG Pitre
Barbara C Vanderhyden
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2012
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/1757-2215-5-39

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Technical challenges and limitations of current mouse models of ovarian cancer

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis

Polycystic ovary syndrome resembling histopathological alterations in ovaries from prenatal androgenized female rats

Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis

Mucinous adenocarcinoma of the intestinal type arising from mature cystic teratoma of the ovary: a rare case report and review of the literature

The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer

Immunoreactivities of androgen receptor, estrogen receptors, p450arom, p450c17 proteins in wild ground squirrels ovaries during the nonbreeding and breeding seasons